Clinical experts establish first-ever global consensus for the appropriate use of intravascular ultrasound (IVUS) in peripheral vascular disease interventions
05 Oktober 2021 - 5:00PM
Clinical experts establish first-ever global consensus for the
appropriate use of intravascular ultrasound (IVUS) in peripheral
vascular disease interventions
October 5, 2021
- First global analysis of IVUS by interventional cardiology,
interventional radiology, and vascular surgery experts in
peripheral vascular disease (PVD) interventions
- Consensus results shared at IVUS symposium by Smith Center of
Outcomes Research during VIVA
Amsterdam, the Netherlands – Royal Philips
(NYSE: PHG, AEX: PHIA), a global leader in health technology and
IVUS solutions, today announced that a worldwide committee of 40
cross-specialty medical experts achieved the first-ever consensus
for the appropriate use of intravascular ultrasound (IVUS) in
peripheral vascular disease (PVD) interventions. The new consensus
and recommendations for use of IVUS aim to improve quality care in
PVD and are based on evidence, expert practice standards, and
clinical experience.
“The results of the cross-specialty expert consensus demonstrate
strong support for the use of IVUS during peripheral
interventions,” said Eric A. Secemsky, MD, Interventional
Cardiologist at Beth Israel Deaconess Medical Center and Assistant
Professor of Medicine at Harvard Medical School, Boston USA.
“Future efforts need to focus on improving IVUS implementation into
clinical practice and streamlining procedural workflow to help
improve our patient outcomes.”
As part of Philips’ peripheral vascular portfolio, IVUS provides
the visualization and guidance essential for the optimal diagnosis
and treatment of patients. Using a miniaturized ultrasound
transducer mounted on the tip of a catheter, it captures real-time,
high-resolution images inside the vessel. IVUS imaging enables
physicians to formulate patient-specific treatment plans and
confirm therapy results.
Today, healthcare providers’ use of IVUS in PVD interventions is
not standardized and is therefore inconsistent. The new
appropriate-use expert consensus may help establish global
standards of care to adopt into guidelines and improve quality care
in PVD.
To achieve consensus, the broad, multi-disciplinary, global
experts used a rigorous methodology. They conducted a systematic
and comprehensive review of key clinical IVUS scenarios and
decision-making processes before voting as world experts in the
field. The results were shared at a special symposium during
Vascular Interventional Advances (VIVA) 2021 (Las Vegas, USA, 5-7
October). Through this method, experts established clinical
consensus to identify optimal use of IVUS and potential gaps to set
a standard across clinical specialties and drive positive outcomes
for patients.
"We commend these global, cross-specialty experts, on their
commitment to identifying the appropriate uses of IVUS to
standardize procedures in order to improve outcomes for peripheral
vascular patients worldwide,” said Chris Landon, Senior Vice
President and General Manager Image Guided Therapy Devices at
Philips. “This expert consensus sets a precedent on how patients
are managed and supports Philips’ commitment to evidence-based
medical guidelines as part of our pursuit of better patient
outcomes, enhanced patient and staff experiences, and lower cost of
care.”
Philips is the global leader in IVUS solutions which are part of
the company’s comprehensive portfolio of systems, smart devices,
software, and services for peripheral vascular disease with the
objective of helping clinicians decide, guide, treat and confirm
the right therapy for each patient during their procedure.
For further information, please contact:
Joost Maltha Philips Global Press Office Tel:
+31 6 10 55
8116 Email: joost.maltha@philips.com
Fabienne van der FeerPhilips Image Guided TherapyTel: + 31 622
698 001E-mail: fabienne.van.der.feer@philips.com
About Royal Philips Royal Philips (NYSE: PHG, AEX: PHIA)
is a leading health technology company focused on improving
people's health and well-being, and enabling better outcomes across
the health continuum – from healthy living and prevention, to
diagnosis, treatment and home care. Philips leverages advanced
technology and deep clinical and consumer insights to deliver
integrated solutions. Headquartered in the Netherlands, the company
is a leader in diagnostic imaging, image-guided therapy, patient
monitoring and health informatics, as well as in consumer health
and home care. Philips generated 2020 sales of EUR 17.3 billion and
employs approximately 77,000 employees with sales and services in
more than 100 countries. News about Philips can be found at
www.philips.com/newscenter.
- Philips intravascular ultrasound (IVUS) imaging - 1
- Philips intravascular ultrasound (IVUS) imaging - 2
Koninklijke Philips NV (BIT:1PHIA)
Historical Stock Chart
Von Mär 2024 bis Apr 2024
Koninklijke Philips NV (BIT:1PHIA)
Historical Stock Chart
Von Apr 2023 bis Apr 2024